Home Drug IndexClinical Monograph

Tramadol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Analgesic

Subclass

Centrally-acting Weak Opioid Analgesic (Atypical Opioid)

Speciality

Pain Medicine

Schedule (India)

Schedule H

Routes

Oral, Intravenous (IV), Intramuscular (IM), Rectal

Formulations

Tablets (Immediate-release): 50 mg, 100 mg
Tablets (Sustained-release): 100 mg, 150 mg, 200 mg
Capsules: 50 mg, 100 mg (includes SR formulations)
Injection: 50 mg/mL (1 mL and 2 mL ampoules)
Suppository: 100 mg (limited availability)
Oral drops / Paediatric liquid formulations: NOT AVAILABLE in India

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Moderate to Moderately Severe Acute Pain (Post-operative, Trauma, Musculoskeletal)

Oral — Immediate-Release Formulation:

Parameter	Dose
Starting dose	50–100 mg orally every 4–6 hours as needed
Titration	Adjust based on pain response and tolerability; increase by 50 mg increments
Usual maintenance dose	200–300 mg/day in divided doses
Maximum dose	400 mg/day

Clinical Notes:

For opioid-naive patients, start at lower end (50 mg)
Use for shortest duration possible (typically ≤5–7 days for acute pain)
Avoid concurrent use with other opioid analgesics
Has serotonergic activity — avoid with SSRIs/SNRIs or use with caution

2. Chronic Non-Malignant Pain (Osteoarthritis, Chronic Back Pain, Neuropathic Component)

Oral — Sustained-Release Formulation:

Parameter	Dose
Starting dose	100 mg orally once daily (or 50 mg twice daily if using IR initially)
Titration	Increase by 50–100 mg/day every 3–5 days based on response and tolerability
Usual maintenance dose	150–300 mg/day (once daily or in two divided doses)
Maximum dose	400 mg/day

Clinical Notes:

Reserve for patients who have not responded to or cannot tolerate non-opioid analgesics (paracetamol, NSAIDs)
Consider tapering and discontinuation if used >2–4 weeks
SR formulations should not be crushed or chewed
Reassess need for continued therapy regularly; dependence risk with prolonged use

3. Postoperative Pain (Parenteral — Hospital/Monitored Setting Only)

Intravenous / Intramuscular:

Parameter	Dose
Starting dose	50–100 mg IV or IM
Titration	Repeat every 4–6 hours as needed based on pain control
Usual maintenance dose	200–400 mg/day in divided doses
Maximum dose	400 mg/day

Administration Notes:

IV injection: Dilute in 10 mL of normal saline and administer slowly over 2–3 minutes to reduce dizziness, nausea, and hypotension
IM injection: Administer deep into large muscle mass
Switch to oral formulation as soon as clinically feasible
Use only in monitored settings with access to resuscitation equipment

Secondary Indications – Adults (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Diabetic Peripheral Neuropathy (OFF-LABEL)	Starting: 50 mg twice daily (IR) OR 100 mg SR once daily; Titration: increase to 100 mg twice daily or 200 mg SR daily; Maximum: 400 mg/day	Evaluate efficacy after 4–6 weeks; discontinue if no benefit	Specialist recommended (Neurology/Pain Medicine)	Multiple RCTs; Indian pain clinic practice; reserve for cases refractory to gabapentin/pregabalin/duloxetine
Cancer Pain — Mild to Moderate (OFF-LABEL)	50–100 mg every 4–6 hours (IR) or 100–200 mg SR twice daily; Maximum: 400 mg/day	As needed for pain control; transition to strong opioids if inadequate	Specialist only (Palliative Care/Oncology)	WHO Pain Ladder Step 2; Indian palliative care protocols
Premature Ejaculation (OFF-LABEL)	25–50 mg orally 1–2 hours before sexual activity; on-demand use only	Intermittent; not for regular daily use	Specialist only (Andrology/Urology)	Limited RCTs show benefit; not approved indication; risk of dependence with repeated use
Restless Legs Syndrome — Refractory (OFF-LABEL)	50–100 mg at bedtime	Long-term if effective	Specialist only (Neurology)	Case series; consider only when dopamine agonists and gabapentinoids have failed

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

⚠️ Tramadol is NOT recommended in children below 12 years of age due to risk of serious respiratory depression, particularly in CYP2D6 ultra-rapid metabolizers.

⚠️ Absolutely contraindicated in patients below 18 years undergoing tonsillectomy and/or adenoidectomy — fatalities reported.

Primary Indications

Moderate to Severe Pain (Children ≥12 years) — Short-term Use Only:

Parameter	Dose
Starting dose	1–2 mg/kg/dose orally (maximum 50–100 mg per dose)
Titration	Not applicable for short-term use
Usual maintenance dose	1–2 mg/kg/dose every 6 hours as needed
Maximum dose	8 mg/kg/day OR 400 mg/day (whichever is lower)

Clinical Notes:

Use only under paediatric pain specialist or surgeon supervision
Limit duration to <5 days
Avoid in patients with history of sleep apnoea, neuromuscular disorders, or severe respiratory conditions
Monitor closely for signs of respiratory depression, excessive sedation

Safety Monitoring:

Respiratory rate and depth
Sedation level (use validated sedation scale)
Oxygen saturation (if available)
GI symptoms (nausea, vomiting, constipation)

Secondary Indications – Paediatrics (Off-label)

Not recommended — insufficient safety data and significant risk of serious adverse events.

Age Restrictions:

Not recommended below 12 years of age under any circumstances
Contraindicated below 18 years for post-tonsillectomy/adenoidectomy pain
Use in adolescents (12–18 years) should be limited to short-term, specialist-supervised settings only

Renal Adjustments

Creatinine Clearance (CrCl)	Recommendation
≥60 mL/min	No adjustment required
30–59 mL/min	Extend dosing interval to every 8 hours; maximum 300 mg/day
15–29 mL/min	Extend dosing interval to every 12 hours; maximum 200 mg/day
<15 mL/min	Avoid; if essential, maximum 100 mg/day with close monitoring
Haemodialysis	Not efficiently removed; accumulation risk; avoid sustained-release formulations; if used, give IR formulation after dialysis session

Additional Notes:

Active metabolite (O-desmethyltramadol) accumulates in renal impairment
Avoid sustained-release formulations in moderate to severe renal impairment
Increased risk of seizures and CNS toxicity with accumulation

Hepatic adjustment

Contraindications

Known hypersensitivity to tramadol or other opioids
Acute intoxication with alcohol, opioids, hypnotics, centrally-acting analgesics, or psychotropic drugs
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs
Uncontrolled epilepsy or history of seizure disorder
Severe hepatic impairment
Severe renal impairment (CrCl <15 mL/min)
Children below 12 years of age
Patients below 18 years undergoing tonsillectomy and/or adenoidectomy
Severe respiratory depression or acute severe bronchial asthma (without monitoring/ventilatory support)
Known or suspected gastrointestinal obstruction (including paralytic ileus)

Cautions

History of seizure disorder or conditions predisposing to seizures (head trauma, metabolic disorders, CNS infection, alcohol/drug withdrawal)
Concurrent use with serotonergic drugs (SSRIs, SNRIs, triptans, TCAs, MAOIs) — risk of serotonin syndrome
Elderly patients — increased sensitivity, slower metabolism, higher fall risk
History of substance abuse or opioid dependence — potential for misuse and addiction
Head injury or raised intracranial pressure — may mask neurological signs
Respiratory conditions (COPD, sleep apnoea, cor pulmonale) — risk of respiratory depression
Mild to moderate hepatic or renal impairment
Concurrent CNS depressants (benzodiazepines, alcohol, antipsychotics)
Patients who are CYP2D6 ultra-rapid metabolisers — increased risk of toxicity
Biliary tract disorders
Adrenal insufficiency
Hypothyroidism
Prostatic hypertrophy or urethral stricture

Pregnancy

Parameter	Information
Overall Safety	Avoid unless clearly necessary; limited human data; animal studies show some risk
Risk	Neonatal withdrawal syndrome if used chronically near term; potential for neonatal respiratory depression
Preferred Alternatives	Paracetamol (first-line for mild-moderate pain); short-course NSAIDs (second trimester only under specialist guidance)
When Use May Be Justified	Short-term use for moderate-severe pain when non-opioid alternatives inadequate; avoid near term; requires obstetric supervision
Monitoring	Fetal movements; neonatal respiratory function and withdrawal symptoms after delivery if used in late pregnancy

Lactation

Parameter	Information
Compatibility	Use with caution; avoid if possible, especially chronic use
Expected Drug Level in Milk	Low (approximately 0.1% of maternal dose reaches infant); however, active metabolite also present
Risk to Infant	Sedation, respiratory depression (particularly if mother is CYP2D6 ultra-rapid metaboliser), feeding difficulties
Preferred Alternatives	Paracetamol; ibuprofen (if NSAID appropriate)
Infant Monitoring	Sedation, alertness, feeding pattern, breathing, apnoea
Precautions	Avoid high doses; limit duration; if single dose used, may breastfeed after 4 hours

Elderly

Parameter	Recommendation
Starting dose	25–50 mg orally every 6–8 hours (use IR formulation initially)
Titration	Increase slowly every 4–5 days; use longer dosing intervals
Maximum recommended	300 mg/day (lower than general adult maximum)
Increased Risks	Falls, confusion, excessive sedation, constipation, urinary retention, respiratory depression
Additional Precautions	Assess renal and hepatic function before dosing; avoid sustained-release formulations in frail or cognitively impaired patients; monitor gait and cognition

Major drug interactions

Interacting Drug	Mechanism	Effect	Management
MAOIs (phenelzine, tranylcypromine, moclobemide, linezolid)	MAO inhibition + serotonergic effect of tramadol	Severe serotonin syndrome, hypertensive crisis, hyperpyrexia	Contraindicated — avoid combination; wait 14 days after stopping MAOI before starting tramadol
SSRIs (fluoxetine, sertraline, escitalopram)	Additive serotonergic effect + CYP2D6 inhibition (fluoxetine, paroxetine)	Serotonin syndrome; reduced conversion to active metabolite	Avoid if possible; if essential, use lowest doses and monitor closely for serotonin syndrome
SNRIs (venlafaxine, duloxetine)	Additive serotonergic effect	Serotonin syndrome	Avoid combination; if essential, monitor closely
Triptans (sumatriptan, rizatriptan)	Additive serotonergic effect	Serotonin syndrome	Avoid concurrent use
Carbamazepine	Strong CYP3A4 induction	Markedly reduced tramadol efficacy (plasma levels reduced by up to 50%)	Consider alternative analgesic; if used, significantly higher doses may be needed
Alcohol	Additive CNS depression	Profound sedation, respiratory depression, increased overdose risk	Avoid concurrent use; patient counselling mandatory
Benzodiazepines / Other Opioids	Additive CNS and respiratory depression	Respiratory depression, sedation, coma, death	Avoid combination if possible; if essential, reduce doses and monitor closely
Ondansetron	5-HT3 antagonism may reduce tramadol analgesia	Reduced analgesic efficacy (some evidence)	Consider alternative antiemetics (metoclopramide)

Moderate drug interactions

Interacting Drug	Effect	Management
Tricyclic Antidepressants (amitriptyline, nortriptyline)	Additive serotonergic and anticholinergic effects; seizure threshold lowering	Monitor for serotonin syndrome and seizures; use with caution
Antipsychotics (haloperidol, risperidone)	Additive seizure threshold lowering	Monitor for seizures; use with caution
Warfarin	Rare reports of increased INR	Monitor INR if chronic tramadol use; adjust warfarin dose as needed
Macrolides (clarithromycin, erythromycin)	CYP3A4 inhibition; increased tramadol levels	Monitor for toxicity; consider dose reduction
Ciprofloxacin	CYP enzyme inhibition	May elevate tramadol levels; monitor for adverse effects
Quinidine	CYP2D6 inhibition	Reduced formation of active metabolite; may reduce efficacy
Digoxin	Rare reports of digoxin toxicity	Monitor digoxin levels if concurrent use
Antiepileptics (phenytoin, phenobarbital)	CYP enzyme induction	Reduced tramadol efficacy
Rifampicin	Strong CYP3A4 induction	Significantly reduced tramadol efficacy
First-generation antihistamines	Additive CNS depression	Use with caution; monitor sedation

Common Adverse effects

Nausea (most common; dose-related)
Vomiting
Dizziness, vertigo
Drowsiness, sedation
Headache
Constipation
Dry mouth
Sweating, diaphoresis
Fatigue, asthenia
Pruritus

Serious Adverse effects

Adverse Effect	Clinical Action
Seizures (dose-related; risk increases >400 mg/day or with interacting drugs)	Discontinue immediately; supportive care; avoid in patients with seizure history
Serotonin syndrome (when combined with serotonergic agents: hyperthermia, rigidity, myoclonus, autonomic instability, mental status changes)	Discontinue all serotonergic drugs immediately; supportive care; cyproheptadine may be used; hospitalisation often required
Respiratory depression (especially with overdose, renal impairment, CYP2D6 ultra-rapid metabolisers, or concurrent CNS depressants)	Discontinue; supportive ventilation; naloxone may partially reverse (high doses may be needed)
Anaphylaxis / Severe allergic reactions	Discontinue permanently; emergency management
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (rare)	Discontinue immediately; hospitalisation; dermatology consultation
Physical dependence and withdrawal syndrome (with prolonged use: anxiety, insomnia, tremor, sweating, piloerection, GI symptoms, rarely seizures)	Taper gradually; do not discontinue abruptly
Hypoglycaemia (rare; reported particularly in diabetics)	Monitor blood glucose; manage hypoglycaemia appropriately
QT prolongation (rare; at high doses or overdose)	Avoid in patients with known QT prolongation; ECG if suspected

Monitoring requirements

Timing	Parameters
Baseline	Pain assessment, renal function (creatinine, eGFR), hepatic function, seizure history, psychiatric history (depression, substance use), concurrent medications (especially serotonergic drugs)
After initiation (1–7 days)	Pain control efficacy, sedation level, respiratory rate, nausea/vomiting, constipation, signs of serotonin syndrome
Long-term (if chronic use)	Signs of tolerance, dependence, or misuse; bowel function (constipation management); cognitive effects (especially in elderly); reassess need for continued therapy every 2–4 weeks
On discontinuation	Taper gradually (reduce by 25–50% every 2–4 days); monitor for withdrawal symptoms

Brands in India

Immediate-Release:

Tramazac™ (Zydus) — 50 mg tablets
Tramadol (Generic) — 50 mg, 100 mg tablets
Contramal™ (Abbott) — 50 mg capsules
Doltram™ — 50 mg tablets

Sustained-Release:

Tramazac SR™ (Zydus) — 100 mg, 200 mg tablets
Dolomed Retard™ — 100 mg, 150 mg tablets
Contramal SR™ — 100 mg, 200 mg tablets

Injection:

Tramadol Injection™ (Various) — 50 mg/mL ampoules
Tramazac Injection™ — 50 mg/mL

Fixed-Dose Combinations (Tramadol + Paracetamol):

Ultracet™ (Janssen) — Tramadol 37.5 mg + Paracetamol 325 mg
Dolokind Plus™ — Tramadol 37.5 mg + Paracetamol 325 mg
Acuvin-T™ — Tramadol 37.5 mg + Paracetamol 325 mg

Note: FDCs with paracetamol are commonly used for short-term acute pain; do not exceed paracetamol 4 g/day from all sources.

Price range (INR)

Formulation	Price Range	Notes
50 mg IR tablet	₹2–₹5 per tablet	—
100 mg IR tablet	₹4–₹8 per tablet	—
100 mg SR tablet	₹5–₹10 per tablet	—
200 mg SR tablet	₹8–₹15 per tablet	—
50 mg/mL injection (1 mL)	₹10–₹18 per ampoule	—
Tramadol + Paracetamol FDC	₹3–₹7 per tablet	—

Regulatory: Not listed under NLEM 2022; not under NPPA price control; prices vary by brand and region

Clinical pearls

Dual mechanism of action — Tramadol is not a pure opioid; it has weak mu-opioid agonism plus serotonin and norepinephrine reuptake inhibition — this accounts for both its efficacy in neuropathic pain and its serotonin syndrome risk
Seizure threshold — Risk of seizures is dose-dependent; do not exceed 400 mg/day; risk increases significantly with concurrent serotonergic drugs, antipsychotics, or in patients with epilepsy
Serotonin syndrome awareness — Do not combine with MAOIs (contraindicated); use extreme caution with SSRIs, SNRIs, triptans, TCAs — educate patients on symptoms (agitation, hyperthermia, tremor, rigidity)
Paediatric restriction — Absolutely avoid in children <12 years; contraindicated in any patient <18 years post-tonsillectomy/adenoidectomy — fatalities have been reported due to ultra-rapid CYP2D6 metabolism
Tramadol + Paracetamol FDCs — Useful for short-term acute pain (≤5 days); do not exceed paracetamol 4 g/day from all sources; superior analgesia with potentially lower tramadol doses
Dependence and tolerance — Physical dependence can develop within 2–4 weeks of regular use; always taper gradually when discontinuing; reassess need for ongoing therapy regularly

Version

RxIndia v1.0 — 01 May 2025

Reference

CDSCO Product Information and Schedule H Listing
Indian Pharmacopoeia (IP)
NLEM 2022 (exclusion noted)
API Textbook of Medicine
AIIMS Drug Formulary and Pain Management Protocols
Indian Association for Study of Pain — Guidelines
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Harrison's Principles of Internal Medicine
Indian Paediatric Association Position Statement on Tramadol in Children
Indian Association of Palliative Care — Opioid Guidelines
FDA Safety Communications on Tramadol in Paediatrics (supportive reference for age restrictions)
RCTs on Tramadol in Neuropathic Pain (off-label evidence)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...